HR-6130-119
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 0.
Sponsored by Vern Buchanan (R-FL)
What it does
This bill would require Medicare to cover blood-based screening tests designed to detect early or pre-symptomatic Alzheimer's disease and related dementias, starting January 1, 2028. Covered tests must be FDA-cleared or approved and include genomic sequencing blood tests or other equivalent tests (such as protein expression or imaging-based tests) that the Secretary of Health and Human Services determines provide comparable results.
Who benefits
Medicare beneficiaries at risk of Alzheimer's disease and related dementias, who would gain access to earlier, less invasive diagnostic testing than current methods like PET scans or spinal taps. Diagnostic test manufacturers developing blood-based dementia screening technology would gain a new reimbursable market. Physicians and dementia care specialists would benefit from earlier diagnostic tools that could inform treatment planning. Family caregivers may benefit from earlier diagnosis allowing more time to plan care.
Who is hurt
Medicare's budget would bear the cost of new coverage, potentially affecting premiums or program financing over time. Providers of existing, more expensive diagnostic methods (PET imaging centers, specialists performing lumbar punctures) could see reduced demand as blood tests substitute for costlier procedures. Patients could face psychological distress from early diagnosis of a currently incurable condition, and some beneficiaries may undergo testing with unclear clinical benefit if treatment options remain limited.
Supporters argue
Supporters argue that blood-based tests are far less invasive and less costly than PET scans or spinal taps, and that early detection allows patients and families to plan care, access clinical trials, and potentially benefit from disease-modifying treatments approved in recent years. They cite the rising prevalence of Alzheimer's among an aging population and contend that Medicare coverage would remove a financial barrier to adopting an emerging technology that could improve early intervention outcomes.
Opponents argue
Opponents argue that mandating coverage for a specific emerging technology category before its clinical utility is fully established could lead Medicare to pay for tests with unclear benefit to patient outcomes, since a positive result does not always change treatment. They contend that broad coverage requirements, once written into statute, are difficult to adjust as science evolves, and that resources might be better directed toward proven interventions or added through the normal coverage-determination process rather than legislation.
Constitutional context
Congress is exercising its Spending Clause authority (Art. I, §8, cl. 1) to define what Medicare, a federal spending program, must cover; this type of program design falls within the broad discretion recognized for federal benefit programs under South Dakota v. Dole (1987) and does not implicate the coercion or mandate concerns addressed in NFIB v. Sebelius (2012), since it expands optional coverage rather than compelling private purchases or coercing states.
Checks and balances
Congress sets the statutory coverage requirement, while HHS implements it through rulemaking determining which specific tests qualify as "equivalent," subject to post-Loper Bright judicial review of that agency interpretation.
Historical precedent
Medicare has previously been amended by Congress to add coverage for specific new diagnostic technologies, such as colorectal cancer screening and lung cancer screening, following similar statutory mandate structures.